ABCAM PLC Block Listing application of Ordinary Shares (2733G)
28 Março 2022 - 11:09AM
UK Regulatory
TIDMABC
RNS Number : 2733G
ABCAM PLC
28 March 2022
For immediate release
28 March 2022
ABCAM PLC
("Abcam" or the "Company")
Block Listing application of Ordinary Shares
Cambridge, UK : Abcam plc (AIM: ABC; Nasdaq: ABCM), a global
leader in the supply of life science research tools, announces that
it has applied for a block admission for a further 4,350,000
ordinary shares of 0.2p each in the Company ("Ordinary Shares") to
be admitted to trading on AIM on 29 March 2022. This will be used
to facilitate the admission of shares to trading following the
exercise of options granted under the following two share
schemes:
-- Abcam Growth Plan - 3,500,000 shares;
-- Annual Bonus Plan - 850,000 shares.
The Company will make six-monthly announcements of the
utilisation of the block admission, in line with its obligations
under AIM Rule 29.
New Ordinary Shares issued following option exercises and
admitted to trading under the block admission will rank pari passu
in all respects with the existing Ordinary Shares.
At the time of this announcement, Abcam plc has 228,908,563
Ordinary Shares in issue.
Date of Notification: 28 March 2022
For further information please contact:
+ 44 (0) 1223 696
Abcam 000
Marc Perkins, Company Secretary
Numis - Nominated Adviser & Joint Corporate + 44 (0) 20 7260
Broker 1000
Garry Levin / Freddie Barnfield / Duncan Monteith
Morgan Stanley - Joint Corporate Broker +44 (0) 20 425
Tom Perry / Luka Kezic 8000
FTI Consulting +44 (0) 20 3727
Ben Atwell / Natalie Garland-Collins 1000
Notes to Editors
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
antibodies, assays and other research tools to address important
targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health.
Abcam's worldwide customer base of approximately 750,000 life
science researchers uses Abcam's antibodies, reagents, biomarkers
and assays. By actively listening to and collaborating with these
researchers, the Company continuously advances its portfolio to
address their needs. A transparent programme of customer reviews
and datasheets, combined with an industry-leading validation
initiative, gives researchers increased confidence in their
results.
Founded in 1998 and headquartered in Cambridge, UK, the Company
has served customers in more than 130 countries. Abcam's ordinary
shares are listed on the London Stock Exchange (AIM: ABC) and its
American Depositary Shares (ADSs) trade on the Nasdaq Global Market
(Nasdaq: ABCM).
For more information, please visit corporate.abcam.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALSSEAFLAEESESD
(END) Dow Jones Newswires
March 28, 2022 10:09 ET (14:09 GMT)
Abcam (LSE:ABC)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Abcam (LSE:ABC)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
